Early reports showed augmented plasma concentrations of IL-6, therefore providing the introduction of anti-IL-6 therapies in randomized clinical trials (143, 144) therefore, novel cytokine inhibitors, including Baricitinib, Anakinra, and Tocilizumab, were likely options for treating severe COVID-19 which found appropriate niches (145–147). Here, IL6 is linked to COVID-19.